 Dacarbazine
"Dacarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
| Descriptor ID |
D003606
|
| MeSH Number(s) |
D02.925.200 D03.383.129.308.240
|
| Concept/Terms |
Dacarbazine- Dacarbazine
- Dimethyl Imidazole Carboxamide
- Carboxamide, Dimethyl Imidazole
- Imidazole Carboxamide, Dimethyl
- DTIC
- ICDT
- Decarbazine
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
- DIC
- Dimethyl Triazeno Imidazole Carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Dacarbazine".
Below are MeSH descriptors whose meaning is more specific than "Dacarbazine".
This graph shows the total number of publications written about "Dacarbazine" by people in this website by year, and whether "Dacarbazine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 3 | 5 | | 2014 | 1 | 4 | 5 | | 2015 | 4 | 4 | 8 | | 2016 | 1 | 5 | 6 | | 2017 | 2 | 3 | 5 | | 2018 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dacarbazine" by people in Profiles.
-
Hernández-Benítez J, López-Azcarraga A, Flerlage JE, Castellino S, Aristizabal P, Hoppe BS, Milgrom SA, de Paula MJA, Mailhot Vega RB. Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations. JCO Glob Oncol. 2025 Jun; 11:e2400485.
-
Germano IM, Ziu M, Wen P, Ormond DR, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun; 158(2):225-253.
-
Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.
-
Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib?±?cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 Aug 03; 18(1):294.
-
Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, Vitolo U, Ansell SM. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? Leuk Lymphoma. 2020 02; 61(2):318-327.
-
Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 10 01; 4(10):1382-1388.
-
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 09 01; 29(9):1995-2002.
-
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
-
Milgrom SA, Pinnix CC, Gunther JR, Fanale M, Dabaja BS. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. Br J Haematol. 2019 01; 184(2):292-293.
-
Bupathi M, Hays JL, Chen JL. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. PLoS One. 2017; 12(11):e0188116.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|